CoChat
Sign Up
Cited by 304Complementary and Alternative Medicine StudiesVitamin C and Antioxidants ResearchNutrition and Health Studies

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects

Open access
Padayatty, Sebastian J., Sun, Andrew Y., Chen, Qi, Espey, Michael Graham, Drisko, Jeanne, Levine, Mark·2010·PLoS ONE
DOI 10.1371/journal.pone.0011414PMC PMC2898816
Open this paper in CoChat — free account

Abstract

BACKGROUND: Anecdotal information and case reports suggest that intravenously administered vitamin C is used by Complementary and Alternate Medicine (CAM) practitioners. The scale of such use in the U.S. and associated side effects are unknown. METHODS AND FINDINGS: We surveyed attendees at annual CAM Conferences in 2006 and 2008, and determined sales of intravenous vitamin C by major U.S. manufacturers/distributors. We also queried practitioners for side effects, compiled published cases, and analyzed FDA's Adverse Events Database. Of 199 survey respondents (out of 550), 172 practitioners administered IV vitamin C to 11,233 patients in 2006 and 8876 patients in 2008. Average dose was 28 grams every 4 days, with 22 total treatments per patient. Estimated yearly doses used (as 25 g/50 ml vials) were 318,539 in 2006 and 354,647 in 2008. Manufacturers' yearly sales were 750,000 and 855,000 vials, respectively. Common reasons for treatment included infection, cancer, and fatigue. Of 9,328 patients for whom data is available, 101 had side effects, mostly minor, including lethargy/fatigue in 59 patients, change in mental status in 21 patients and vein irritation/phlebitis in 6 patients. Publications documented serious adverse events, including 2 deaths in patients known to be at risk for IV vitamin C. Due to confounding causes, the FDA Adverse Events Database was uninformative. Total numbers of patients treated in the US with high dose vitamin C cannot be accurately estimated from this study. CONCLUSIONS: High dose IV vitamin C is in unexpectedly wide use by CAM practitioners. Other than the known complications of IV vitamin C in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency, high dose intravenous vitamin C appears to be remarkably safe. Physicians should inquire about IV vitamin C use in patients with cancer, chronic, untreatable, or intractable conditions and be observant of unexpected harm, drug interactions, or benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0011414

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cumulative total and the distribution of patients treated among the survey respondents. Practitioners were grouped according to the number of patients whom they treated with IV vitamin C in the preceding twelve months. For ease of display, number of patients were divided into arbitrary ranges which are shown on the X axis. The number of practitioners who treated the specified number of patients are shown on the Y axis. Patients were unevenly distributed among survey respondents. In 2006, out of 106 practitioners who responded to the survey, 13 did not use high dose IV vitamin C, 30 respondents treated more than 100 patients each, and 3 treated 1000 or more patients (Fig 1A). For 2008, the corresponding numbers were 93, 14, 18 and 2 respectively (Fig 1B). Cumulative total of patients treated by all practitioners are shown as line diagrams (scaled to Y axis on right).
Figure 1 Cumulative total and the distribution of patients treated among the survey respondents. Practitioners were grouped according to the number of patients whom they treated with IV vitamin C in the preceding twelve months. For ease of display, number of patients were divided into arbitrary ranges which are shown on the X axis. The number of practitioners who treated the specified number of patients are shown on the Y axis. Patients were unevenly distributed among survey respondents. In 2006, out of 106 practitioners who responded to the survey, 13 did not use high dose IV vitamin C, 30 respondents treated more than 100 patients each, and 3 treated 1000 or more patients (Fig 1A). For 2008, the corresponding numbers were 93, 14, 18 and 2 respectively (Fig 1B). Cumulative total of patients treated by all practitioners are shown as line diagrams (scaled to Y axis on right).CC0 · PubMed Central
Figure 2 Number of practitioners who used intravenous vitamin C for various conditions. X axis shows the number of practitioners who used intravenous vitamin C to treat each of the conditions listed on the Y axis. Blue bars denote infections, red bars denote cancers, and green bars denote other indications. Data for 2006 (solid bars) and 2008 (hatched bars) show that intravenous vitamin C was most often used to treat infections and cancer. Indications for which less than four practitioners used high dose intravenous vitamin C are listed in Table S1.
Figure 2 Number of practitioners who used intravenous vitamin C for various conditions. X axis shows the number of practitioners who used intravenous vitamin C to treat each of the conditions listed on the Y axis. Blue bars denote infections, red bars denote cancers, and green bars denote other indications. Data for 2006 (solid bars) and 2008 (hatched bars) show that intravenous vitamin C was most often used to treat infections and cancer. Indications for which less than four practitioners used high dose intravenous vitamin C are listed in Table S1.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. HD Riordan, 1990, Case study: high-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney., J Orthomolecular Med, 5, 5

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Padayatty, S. J., Sun, A. Y., Chen, Q., Espey, M. G., Drisko, J., & Levine, M.
Affiliations
  • National Institutes of Health (US)
  • University of Kansas Medical Center (US)
Corresponding author
Levine, Mark
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2010-07-07
Volume
5
Issue
7
Pages
e11414
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0011414
PMC
PMC2898816
OpenAlex
W2108045872
Cited by
304
References
53
Citations by year
2026: 8 · 2025: 9 · 2024: 17 · 2023: 15 · 2022: 25 · 2021: 25 · 2020: 27 · 2019: 15 · 2018: 23 · 2017: 13 · 2016: 21 · 2015: 20 · 2014: 24 · 2013: 29 · 2012: 16
FWCI
49.62
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Vitamin C and Antioxidants Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutrition and Health Studies
Keywords
intravenous vitamin C, high-dose vitamin C, adverse effects, phlebitis, lethargy, cancer therapy, drug interactions, renal dysfunction, glucose-6-phosphate dehydrogenase deficiency
MeSH terms
Complementary Therapies, Ascorbic Acid, Data Collection, Humans, Injections, Intravenous, United States, United States Food and Drug Administration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review